• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Pneumonia Unveiled: A Comprehensive Exploration of Causes, Symptoms, and Prevention
  • VIEWS 17
  • PDF 8

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v23.4.84

Year: 2024, Volume: 23, Issue: 4, Pages: 199-203

Review Article

Pneumonia Unveiled: A Comprehensive Exploration of Causes, Symptoms, and Prevention

Rashmi Wani1,∗, Sunny Roy2, Darsh Jain2, Shreya Menon2

1Assistant Professor, Department of Pharmaceutical Chemistry, Vivekanand Education Society’s College of Pharmacy, Affiliated to University of Mumbai, Chembur, Mumbai, 400074, Maharashtra, India
2Student of Final Year B Pharm, Vivekanand Education Society’s College of Pharmacy, Affiliated to University of Mumbai, Chembur, Mumbai, 400074, Maharashtra, India

*Corresponding Author
Email: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

A major contributor to atypical community-acquired pneumonia, Mycoplasma pneumoniae poses a special challenge in the clinical and scientific arenas because of its unique features, which include its tiny genome size, absence of a cell wall, and capacity to elude host immune responses. The many aspects of Mycoplasma pneumoniae infections, including epidemiology, etiology, clinical symptoms, and diagnostic methods, are thoroughly reviewed in this study. A critical examination of existing treatment techniques and emerging therapeutic options is presented, coupled with an exploration of the changing terrain of antibiotic resistance in strains of Mycoplasma pneumoniae. Comprehensive knowledge of this sneaky pathogen is aided by insights into immune evasion mechanisms, host-pathogen interactions, and the function of Mycoplasma pneumoniae in chronic respiratory infections. This review is a useful resource for physicians, researchers, and other healthcare professionals by combining current scientific findings with clinical viewpoints.

Keywords: Mycoplasma pneumoniae; Respiratory illness; COVID-19; Epidemics

References

  1. Abdulhadi B, Kiel J. Mycoplasma Pneumonia. Treasure Island, Finland. Stat Pearls Publishing. 2023.
  2. Ng CK, Chan JWM, Kwan TL, To TS, Chan YH, Ng FYY, et al. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax. 2004;59(10):889–891. Available from: https://doi.org/10.1136/thx.2004.023762
  3. Daxboeck F, Eisl B, Burghuber C, Memarsadeghi M, Assadian O, GS. Fatal Mycoplasma pneumoniae pneumonia in a previously healthy 18-year-old girl. Wiener klinische Wochenschrift. 2007;119:379–384. Available from: https://doi.org/10.1007/s00508-007-0810-7
  5. Gadsby NJ, Reynolds AJ, McMenamin J, Gunson RN, McDonagh S, Molyneaux PJ, et al. Increased reports of Mycoplasma pneumoniae from laboratories in Scotland in 2010 and 2011 – impact of the epidemic in infants. Eurosurveillance . 2012;17(10):1–4. Available from: https://doi.org/10.2807/ese.17.10.20110-en
  6. Ning G, Wang X, Wu D, Yin Z, Li Y, Wang H, et al. The etiology of community-acquired pneumonia among children under 5 years of age in mainland China, 2001–2015: A systematic review. Human Vaccines & Immunotherapeutics. 2017;13(11):2742–2750 . Available from: https://doi.org/10.1080/21645515.2017.1371381
  7. Nakanishi Y, Ito A, Tachibana H, Kawataki M, Ishida T. Comparative prospective cohort study of efficacy and safety according to dosage and administration of ceftriaxone for community-acquired pneumonia. Journal of Infection and Chemotherapy. 2024;p. 1–6. Available from: https://doi.org/10.1016/j.jiac.2024.09.005
  8. Jacobs E, Ehrhardt I, Dumke R. New insights in the outbreak pattern of Mycoplasma pneumoniae. International Journal of Medical Microbiology. 2015;305(7):705–708. Available from: https://doi.org/10.1016/j.ijmm.2015.08.021
  9. Jiang W, Yu H, Wan Z. Mycoplasma pneumoniae infections in children in China: regional and seasonal variations. Pediatr Pulmonol. 2014;49(4):329–334.
  10. Kannan TR, Hardy RD, Coalson JJ, et al. Fatal Outcomes in Family Transmission of Mycoplasma pneumoniae. Clinical Infectious Diseases . 2011;54(2):225–231. Available from: https://doi.org/10.1093/cid/cir769
  11. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clinical Microbiology Reviews. 2004;17(4):697–728. Available from: https://doi.org/10.1128/cmr.17.4.697-728.2004
  12. Waites KB, Talkington DF. Mycoplasma pneumoniae and Its Role as a Human Pathogen. Clinical Microbiology Reviews . 2004;17(4):697–728. Available from: https://doi.org/10.1128/cmr.17.4.697-728.2004
  13. Yoo B, Yune I, Kang D, Cho Y, Lim SY, Yoo S. Etiology and Clinical Prediction of Community-Acquired Lower Respiratory Tract Infection in Children. Journal of Korean Medical Science. 2025;40:1–12. Available from: https://doi.org/10.3346/jkms.2025.40.e5
  14. Vervloet LA, Marguet C, Camargos PAM. Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias. Brazilian Journal of Infectious Diseases . 2007;11(5):507–514. Available from: https://doi.org/10.1590/S1413-86702007000500012
  15. Li Y, Zhai Y, Lin Y, Lu C, He Z, Wu S, et al. Epidemiology of respiratory syncytial virus in hospitalized children with community-acquired pneumonia in Guangzhou: a 10-year study. Journal of Thoracic Disease. 2023;15(3):967–976. Available from: https://doi.org/10.21037/jtd-22-331
  17. Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, et al. COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children A Multinational Study. Pediatric Infectious Disease Journal. 2021;40(1). Available from: journals.lww.com/pidj/abstract/2021/01000/covid_19_and_multisystem_inflammatory_syndrome_in.1.aspx
  18. Miyashita N, Kawai Y, Inamura N, et al. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. Journal of Infection and Chemotherapy. 2015;21(3):153–160. Available from: https://doi.org/10.1016/j.jiac.2014.10.008
  20. Onozuka D, Hashizume M, AH. Impact of weather factors on Mycoplasma pneumoniae pneumonia. Thorax. 2009;64:507–511. Available from: https://thorax.bmj.com/content/64/6/507.citation-tools
  21. Pereyre S, Touati A, Petitjean-Lecherbonnier J, Charron A, Vabret A, Bébéar C. The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. Clinical Microbiology and Infection. 2013;19(4):E212–E217. Available from: https://doi.org/10.1111/1469-0691.12107
  22. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet: Respiratory Medicine. 2020;8(8):807–815. Available from: https://doi.org/10.1016/S2213-2600(20)30225-3
  23. Brugge SvdSvd, Talman S, Winter LJMBd, Mol Md, Hoefman E, Etten RWv, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respiratory Medicine. 2021;176:1–4. Available from: https://doi.org/10.1016/j.rmed.2020.106272

Copyright

© 2024 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 20 January 2025

Year: 2024, Volume: 23, Issue: 4


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.